Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 865-874

  Heidel, Florian ^a   Lipka, Daniel B ^b   Mirea, Fian K ^b   Mahboobi, Siavosh ^c   Grundler, Rebekka ^d   Kancha, Rama K ^d   Duyster, Justus ^d   Naumann, Michael ^a   Huber, Christoph ^b   Böhmer, Frank D ^e   Fischer, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acute myeloid leukaemia; Fms like tyrosine kinase 3; Resistance; Small molecule; Tyrosine kinase inhibitor

Indexed keywords

BIS(1H INDOL 2 YL)METHANONE DERIVATIVE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM REPEAT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; STAUROSPORINE; TANDEM REPEAT SEQUENCES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 60749136351     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07567.x     Document Type: Article

References (33)

1. Breitenbuecher, F., Schnittger, S., Grundler, R., Markova, B., Carius, B., Brecht, A., Duyster, J., Haferlach, T., Huber, C. Fischer, T. (2008) Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood, doi :.
2. von Bubnoff, N., Sänger, J., Peschel, C. Duyster, J. (2007 The FLT3 inhibitor PKC412 displays a limited set of specific FLT3-ITD resistance mutations which in a cell-based screen is not overlapping with the su5614 resistance profile. Onkologie, 30, 108 (abstract P449).
3. Chou, T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58, 621 681.
4. Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J.J., Griffin, J.D., Marynen, P. Gilliland, D.G. (2004) Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Research, 64, 6385 6389.
5. DeAngelo, D.J., Stone, R.M., Heaney, M.L., Nimer, S.D., Paquette, R.L., Klisovic, R.B., Caligiuri, M.A., Cooper, M.R., Lecerf, J.M., Karol, M.D., Sheng, S., Holford, N., Curtin, P.T., Druker, B.J. Heinrich, M.C. (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 108, 3674 3681.
6. Frohling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. Dohner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372 4380.
7. Furet, P., Bold, G., Meyer, T., Roesel, J. Guagnano, V. (2006) Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. Journal of Medicinal Chemistry, 49, 4451 4454.
8. Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M. Clark, R.E. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1302 1311.
9. Graf, C., Heidel, F., Tenzer, S., Radsak, M.P., Solem, F.K., Britten, C.M., Huber, C., Fischer, T. Wolfel, T. (2007) A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood, 109, 2985 2988.
10. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J. Saxena, K. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Molecular Cell, 13, 169 178.
11. Heidel, F., Solem, F.K., Breitenbuecher, F., Lipka, D.B., Kasper, S., Thiede, M.H., Brandts, C., Serve, H., Roesel, J., Giles, F., Feldman, E., Ehninger, G., Schiller, G.J., Nimer, S., Stone, R.M., Wang, Y., Kindler, T., Cohen, P.S., Huber, C. Fischer, T. (2006) Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 107, 293 300.
12. Kancha, R.K., Grundler, R., Peschel, C. Duyster, J. (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental Hematology, 35, 1522 1526.
13. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310 318.
14. Kindler, T., Breitenbuecher, F., Kasper, S., Stevens, T., Carius, B., Gschaidmeier, H., Huber, C. Fischer, T. (2003) In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia, 17, 999 1009.
15. Kindler, T., Breitenbuecher, F., Marx, A., Beck, J., Hess, G., Weinkauf, B., Duyster, J., Peschel, C., Kirkpatrick, C.J., Theobald, M., Gschaidmeier, H., Huber, C. Fischer, T. (2004) Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 103, 3644 3654.
16. Kindler, T., Breitenbuecher, F., Kasper, S., Estey, E., Giles, F., Feldman, E., Ehninger, G., Schiller, G., Klimek, V., Nimer, S.D., Gratwohl, A., Choudhary, C.R., Mueller-Tidow, C., Serve, H., Gschaidmeier, H., Cohen, P.S., Huber, C. Fischer, T. (2005) Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood, 105, 335 340.
17. Knapper, S., Burnett, A.K., Littlewood, T., Kell, W.J., Agrawal, S., Chopra, R., Clark, R., Levis, M.J. Small, D. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 108, 3262 3270.
18. Lowenberg, B., Suciu, S., Archimbaud, E., Haak, H., Stryckmans, P., de Cataldo, R., Dekker, A.W., Berneman, Z.N., Thyss, A., van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G. Zittoun, R. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology, 16, 872 881.
19. Mahboobi, S., Uecker, A., Sellmer, A., Cenac, C., Hocher, H., Pongratz, H., Eichhorn, E., Hufsky, H., Trumpler, A., Sicker, M., Heidel, F., Fischer, T., Stocking, C., Elz, S., Bohmer, F.D. Dove, S. (2006) Novel bis(1H-indol-2-yl) methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. Journal of Medicinal Chemistry, 49, 3101 3115.
20. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R., Frei, E. The Cancer and Leukemia Group B (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896 903.
21. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F.D., Muller-Tidow, C., Berdel, W.E. Serve, H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164 3173.
22. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911 1918.
23. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods, 139, 271 279.
24. O'Hare, T., Eide, C.A. Deininger, M.W. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 110, 2242 2249.
25. Piloto, O., Nguyen, B., Huso, D., Kim, K.T., Li, Y., Witte, L., Hicklin, D.J., Brown, P. Small, D. (2006) IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Research, 66, 4843 4851.
26. Piloto, O., Wright, M., Brown, P., Kim, K.T., Levis, M. Small, D. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood, 109, 1643 1652.
27. Reindl, C., Bagrintseva, K., Vempati, S., Schnittger, S., Ellwart, J.W., Wenig, K., Hopfner, K.P., Hiddemann, W. Spiekermann, K. (2006) Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood, 107, 3700 3707.
28. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L., Schiffer, C.A. The Cancer and Leukemia Group, B (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine, 332, 1671 1677.
29. Stone, R.M., DeAngelo, D.J., Klimek, V., Galinsky, I., Estey, E., Nimer, S.D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., Fox, E.A., Neuberg, D., Clark, J., Gilliland, D.G. Griffin, J.D. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 105, 54 60.
30. Stone, R.M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C.A., Ehninger, G., Cortes, J., Kantarjian, H., DeAngelo, D.A., Massimini, G., Li, X., Phillips, P. Giles, F. (2006) Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood (ASH Annual Meeting Abstracts), 108, 157.
31. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
32. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434 2439.
33. Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y. Naoe, T. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 1605 1609.